

Traumeel® and Zeel T® for treatment of painful osteoarthritis of the knee: The MOZArT trial²



Full title

Multicenter, Double-blind, Randomized Controlled Trial to Evaluate Efficacy and Safety of Co-administered Traumeel® / Zeel® Intra-articular Injections vs. Placebo in Patients With Moderate-to-Severe Pain with Osteoarthritis of the Knee (MOZArT: Management of Osteoarthritis of the Knee with Zeel® And Traumeel® Injections)

INTERVENTIONS



Traumeel®
Zeel T®



Saline control as placebo



Objective

To assess change in knee pain from baseline to end-of-study



Participants


232 patients with moderate to severe pain associated with knee osteoarthritis were recruited from 24 study sites



Design

Prospective, multicenter, parallel-group, double-blind, placebo (saline)-controlled randomized clinical trial

Significant reduction in pain
WOMAC A[†] knee pain subscale (lower is better)



— The co-administered treatment of Traumeel® and Zeel T® provided statistically significant^{††} and clinically relevant pain relief on Days 15 to 99 compared with saline control.

— Safety profile showed no serious adverse events related to the treatment.

— The results of this trial support consideration of Traumeel® and Zeel T® as a therapeutic approach for patients with OA of the knee who fail to respond to standard-of-care pain treatments, or who are at risk due to comorbidities or adverse events.

[†]Western Ontario and McMaster Universities Osteoarthritis Index

^{††}Except day 29